Brightseed, a biosciences company and creator of Forager, a computational platform that illuminates the connections between nature and human health, announced $68 million in Series B funding led by Temasek, with participation from existing and new investors. The new funding will enable Brightseed to advance natural compound discovery and clinical validation and launch the company’s first FDA-GRAS ingredient from a new commercialization center in Raleigh, North Carolina.
“Nature holds an incredibly rich and largely uncharted source of powerful, natural bioactives that create health benefits in humans, and we’re now able to access and integrate them into products for food and health industries,” said Jim Flatt, PhD., co-founder and CEO of Brightseed. “Discovering and mapping natural bioactives to human health benefits was just the first step for Brightseed. Now, we’re launching clinically-studied ingredients and insights to illuminate the hidden potential in nature to restore human health.”
Created by Lee Chae, PhD., Brightseed’s co-founder, CTO, and former researcher at the Stanford Carnegie Institute of Plant Biology, Forager systematically identifies natural bioactives and maps their connection to human health benefits at an unprecedented depth and rate. This accelerated discovery of health-benefiting compounds has potential implications for food & agriculture, nutrition policy, and nature-based drug design.
“Consumers are increasingly looking for natural and accessible solutions to restore their health, but the industry has been severely limited by a lack of tools and technologies to look more deeply into nature’s potential to do that,” said Sofia Elizondo, co-founder, and COO. “Brightseed is building the opportunity space for health innovation rooted in nature and delivering a clear path forward for clinical validation. We are eager to make our bioactives readily accessible for food and health industries as we move from lab to shelf and embrace consumers along the journey of bioactive discovery.”